That means you cannot legitimately place 10.8% for cagrilintide next to 24.2% for retatrutide and declare a winner, because those numbers come from different trials, different populations, different durations (26 vs 48 weeks), different doses, and critically a monotherapy figure for one versus a monotherapy figure for the other, while cagrilintides strongest data are actually as a combination
Three times weekly dosing on a Monday, Wednesday, Friday schedule reduces peaks by 35% with a peak-to-trough ratio of 1.6
Your bariatric surgeon will look at your health history and discuss your goals for your health and weight loss to help determine which one is right for you
In the large SUSTAIN and PIONEER trials, only about 2060% of the CRP reduction was explained by weight and glycaemia
Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial
That may include weight loss, improved insulin sensitivity, reduced visceral fat, better cardiometabolic markers, lower inflammatory burden, improved mobility, and greater capacity to exercise
